Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

STATs in NK-Cells: The Good, the Bad, and the Ugly.

Gotthardt D, Sexl V.

Front Immunol. 2017 Jan 18;7:694. doi: 10.3389/fimmu.2016.00694. eCollection 2016. Review.

2.

Boosting of post-exposure human T-cell and B-cell recall responses in vivo by Burkholderia pseudomallei-related proteins.

Nithichanon A, Gourlay LJ, Bancroft GJ, Ato M, Takahashi Y, Lertmemongkolchai G.

Immunology. 2017 May;151(1):98-109. doi: 10.1111/imm.12709. Epub 2017 Feb 9.

PMID:
28066900
3.

Chicken-Specific Kinome Array Reveals that Salmonella enterica Serovar Enteritidis Modulates Host Immune Signaling Pathways in the Cecum to Establish a Persistence Infection.

Kogut MH, Swaggerty CL, Byrd JA, Selvaraj R, Arsenault RJ.

Int J Mol Sci. 2016 Jul 27;17(8). pii: E1207. doi: 10.3390/ijms17081207.

4.

NK Cell Proliferation Induced by IL-15 Transpresentation Is Negatively Regulated by Inhibitory Receptors.

Anton OM, Vielkind S, Peterson ME, Tagaya Y, Long EO.

J Immunol. 2015 Nov 15;195(10):4810-21. doi: 10.4049/jimmunol.1500414. Epub 2015 Oct 9.

5.

A comprehensive review of pacritinib in myelofibrosis.

Verstovsek S, Komrokji RS.

Future Oncol. 2015;11(20):2819-30. doi: 10.2217/fon.15.200. Epub 2015 Sep 14. Review.

6.

Comparison of predicted and actual consequences of missense mutations.

Miosge LA, Field MA, Sontani Y, Cho V, Johnson S, Palkova A, Balakishnan B, Liang R, Zhang Y, Lyon S, Beutler B, Whittle B, Bertram EM, Enders A, Goodnow CC, Andrews TD.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):E5189-98. doi: 10.1073/pnas.1511585112. Epub 2015 Aug 12.

7.

IL-15-PI3K-AKT-mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells.

Ali AK, Nandagopal N, Lee SH.

Front Immunol. 2015 Jul 20;6:355. doi: 10.3389/fimmu.2015.00355. eCollection 2015. Review.

8.

Interleukin-22: immunobiology and pathology.

Dudakov JA, Hanash AM, van den Brink MR.

Annu Rev Immunol. 2015;33:747-85. doi: 10.1146/annurev-immunol-032414-112123. Epub 2015 Feb 11. Review.

9.

NK cells and their ability to modulate T cells during virus infections.

Cook KD, Waggoner SN, Whitmire JK.

Crit Rev Immunol. 2014;34(5):359-88. Review.

10.

The molecular regulation of Janus kinase (JAK) activation.

Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN.

Biochem J. 2014 Aug 15;462(1):1-13. doi: 10.1042/BJ20140712. Review.

11.

The Critical Role of IL-15-PI3K-mTOR Pathway in Natural Killer Cell Effector Functions.

Nandagopal N, Ali AK, Komal AK, Lee SH.

Front Immunol. 2014 Apr 23;5:187. doi: 10.3389/fimmu.2014.00187. eCollection 2014.

12.

Human lymphoid development in the absence of common γ-chain receptor signaling.

Kohn LA, Seet CS, Scholes J, Codrea F, Chan R, Zaidi-Merchant S, Zhu Y, De Oliveira S, Kapoor N, Shah A, Abdel-Azim H, Kohn DB, Crooks GM.

J Immunol. 2014 Jun 1;192(11):5050-8. doi: 10.4049/jimmunol.1303496. Epub 2014 Apr 25.

13.

Regulation of mouse NK cell development and function by cytokines.

Marçais A, Viel S, Grau M, Henry T, Marvel J, Walzer T.

Front Immunol. 2013 Dec 12;4:450. doi: 10.3389/fimmu.2013.00450. Review.

14.

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Gäbler K, Behrmann I, Haan C.

JAKSTAT. 2013 Jul 1;2(3):e25025. doi: 10.4161/jkst.25025. Epub 2013 May 14. Review.

15.

STATs and macrophage fusion.

Miyamoto T.

JAKSTAT. 2013 Jul 1;2(3):e24777. doi: 10.4161/jkst.24777. Epub 2013 Apr 23. Review.

16.

JAK-STAT and bone metabolism.

Li J.

JAKSTAT. 2013 Jul 1;2(3):e23930. doi: 10.4161/jkst.23930. Epub 2013 Aug 15. Review.

17.

Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.

Migita K, Izumi Y, Torigoshi T, Satomura K, Izumi M, Nishino Y, Jiuchi Y, Nakamura M, Kozuru H, Nonaka F, Eguchi K, Kawakami A, Motokawa S.

Clin Exp Immunol. 2013 Dec;174(3):356-63. doi: 10.1111/cei.12190.

18.

Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma.

Chen Y, Lan Q, Zheng T, Zhao N, Holford TR, Lerro C, Dai M, Huang H, Liang J, Ma S, Leaderer B, Boyle P, Chanock S, Rothman N, Zhang Y.

Leuk Res. 2013 Sep;37(9):1120-4. doi: 10.1016/j.leukres.2013.05.003. Epub 2013 Jun 12.

19.

Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Gomez-Puerta JA, Mócsai A.

Curr Top Med Chem. 2013;13(6):760-73. Review.

20.

Regulation of murine natural killer cell commitment.

Huntington ND, Nutt SL, Carotta S.

Front Immunol. 2013 Jan 30;4:14. doi: 10.3389/fimmu.2013.00014. eCollection 2013.

Supplemental Content

Support Center